PPARG and alcoholic liver diseases: The possible anti-inflammatory mechanism of empagliflozin is recently explained by Abdelhamid et al., who revealed that empagliflozin efficiently interfered with the NF-κB/Nrf-2/PPAR-γ signaling pathway in an experimental model of alcoholic liver disease [39].